Methotrexate plasma decay kinetics: possible alteration in patients undergoing gut sterilization.
作者信息
Creaven P J, Cohen M H, Allen L M
出版信息
Br J Cancer. 1976 Nov;34(5):571-5. doi: 10.1038/bjc.1976.213.
Abstract
摘要
相似文献
1
Methotrexate plasma decay kinetics: possible alteration in patients undergoing gut sterilization.甲氨蝶呤血浆衰减动力学：肠道除菌患者中可能的改变。
Br J Cancer. 1976 Nov;34(5):571-5. doi: 10.1038/bjc.1976.213.
2
Pharmacokinetics and organ distribution of methotrexate in the rat.甲氨蝶呤在大鼠体内的药代动力学及器官分布
Pharmacology. 1981;23(2):75-81. doi: 10.1159/000137531.
3
Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate.人小细胞肺癌细胞系对甲氨蝶呤敏感性的决定因素。
J Clin Invest. 1985 Oct;76(4):1323-9. doi: 10.1172/JCI112106.
4
[Mathematical models of pharmacokinetics in chemotherapy].[化疗中药代动力学的数学模型]
Pharmazie. 1976;31(12):825-39.
5
Increased plasma and tumor somatostatin-like immunoreactivity in medullary thyroid carcinoma and small cell lung cancer.
J Clin Endocrinol Metab. 1981 Feb;52(2):187-94. doi: 10.1210/jcem-52-2-187.
6
Drug interactions with methotrexate.
J Rheumatol Suppl. 1985 Dec;12 Suppl 12:15-20.
7
The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide.食物及同步化疗对口服依托泊苷生物利用度的影响。
Br J Cancer. 1985 Sep;52(3):363-7. doi: 10.1038/bjc.1985.202.
8
[Hormone-producing tumor of the lung].[肺的激素分泌性肿瘤]
Nihon Rinsho. 1978 May;Suppl:1916-7.
9
bcl-2 and prognosis in non-small-cell lung carcinoma.
N Engl J Med. 1994 Jun 16;330(24):1757-8.
10
[Experimental study on pharmacokinetics of methotrexate and its metabolite (7-hydroxy-methotrexate) in tissue].
Gan To Kagaku Ryoho. 1982 Oct;9(10):1678-87.
引用本文的文献
1
Clinical management of cytotoxic drug overdose.细胞毒性药物过量的临床管理。
Med Toxicol Adverse Drug Exp. 1988 Jul-Aug;3(4):253-63. doi: 10.1007/BF03259938.
2
Pharmacokinetic drug interactions of commonly used anticancer drugs.常用抗癌药物的药代动力学药物相互作用。
Clin Pharmacokinet. 1986 May-Jun;11(3):223-35. doi: 10.2165/00003088-198611030-00004.
3
High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach.
Cancer Chemother Pharmacol. 1979;3(3):189-96. doi: 10.1007/BF00262421.
4
[Cytostatica and small intestine (author's transl)].[细胞抑制剂与小肠（作者译）]
Klin Wochenschr. 1978 Jun 15;56(12):579-92. doi: 10.1007/BF01477006.
本文引用的文献
1
Reinvestigation of methotrexate metabolism in rodents.啮齿动物中甲氨蝶呤代谢的再研究。
Biochem Pharmacol. 1970 Nov;19(11):2923-5. doi: 10.1016/0006-2952(70)90031-6.
2
Antibiotics alter methotrexate metabolism and excretion.
Science. 1969 Nov 14;166(3907):887-8. doi: 10.1126/science.166.3907.887.
3
Protected environment-prophylactic antibiotic program in the chemotherapy of acute leukemia.
Am J Med Sci. 1971 Sep;262(3):138-51. doi: 10.1097/00000441-197109000-00001.
4
Studies of the metabolism of methotrexate by intestinal flora. I. Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N 10 -methylpteroic acid.
Biochem Pharmacol. 1972 Mar 15;21(6):821-31. doi: 10.1016/0006-2952(72)90125-6.
5
Methotrexate in liver and bile after intravenous dosage in man.人体静脉注射甲氨蝶呤后在肝脏和胆汁中的情况。
Br J Cancer. 1973 Dec;28(6):589-91. doi: 10.1038/bjc.1973.190.
6
Separation of methotrexate and nonmethotrexate components in rat plasma.大鼠血浆中甲氨蝶呤与非甲氨蝶呤成分的分离。
J Pharm Sci. 1973 Dec;62(12):2056-7. doi: 10.1002/jps.2600621240.
7
Pharmacokinetics of methotrexate.
Clin Pharmacol Ther. 1973 Jul-Aug;14(4):572-9. doi: 10.1002/cpt1973144part1572.
8
Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia.保护环境与预防性抗生素。关于它们在急性白血病治疗中效用的前瞻性对照研究。
N Engl J Med. 1973 Mar 8;288(10):477-83. doi: 10.1056/NEJM197303082881001.
9
The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.
Cancer Res. 1965 Aug;25(7):1018-24.
10
A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients.
Cancer. 1973 Dec;32(6):1490-8. doi: 10.1002/1097-0142(197312)32:6<1490::aid-cncr2820320628>3.0.co;2-6.
Zotero 插件